Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Disease area: Respiratory infections

Abstract

Study objective: It has been hypothesised that an excessive cytokine release was related to poorer outcome. There are no many studies aiming to investigate lung and systemic inflammation in community-acquired pneumonia (CAP) when response to treatment is inadequate.
The aim of this study was to evaluate the cytokines profile -tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), IL-8 and IL-10- in treatment failure of CAP, both locally and in blood.
Design and methods: An observational prospective study was carried in two groups. Group of patients who developed treatment failure (TF) and a control group without evidence of infection. Peripheral blood and bronchoalveolar lavage (BAL) fluid samples were collected at diagnosis. TNF-α, IL-6, IL-8 and IL-10 were measured using commercial ELISA. Results: Twenty-three patients with CAP failure (mean age 60.8± 3 years; 16 men), and sixteen controls (mean age 62.5±10 years; 14 men) were included. Results are in the table 1.

Citokynes(pg/mL)	Treatment failure(n=23)	Control(n=16)	p value*
IL-6 serum	388 ± 636.2	3.2 ± 4.4	0.003
IL-6 BAL	330.4 ± 421.6	35.8 ± 45.7	<0.01
IL-8 serum	74.4 ± 84	24 ± 15.6	NS
IL-8 BAL	8096.4 ± 9803.5	230 ± 547.6	<0.01
TNF-a serum	0.1 ± 0.34	1 ± 0	0.04
TNF-a BAL	4 ± 5.3	2.2 ± 1.3	NS
IL-10 serum	27.7 ± 25.6	4 ± 3	0.01
IL-10 BAL	9.12 ± 13	2.9 ± 2.8	NS

Results are expressed as mean ± SD. *p: Mann-Whitney U test.

Conclusions: Pulmonary inflammatory response in treatment failure CAP is higher locally than systemically, mainly regarding IL-8.

Rating:

Share or cite this content

Citations should be made in the following way:
MJ. Lorenzo, I. Moret, E. Cases, B. Sarria, R. Martinez, S. Reyes, R. Menendez (Valencia, Spain). Community-aquired pneumonia: systemic and local inflammatory response in treatment failure. Eur Respir J 2008; 32: Suppl. 52, 1559

Member's Comments

Vicente Maciangisber - 05.10.2008 11:26
un amigo
felicitaciones por tu estado de buena esperanza y por tu capacidad cientifica reconocida internacionalmente. un abrazo.

Related content which might interest you: Differences between local and systemic inflammatory response in patients with community acquired pneumonia (CAP) Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia Year: 2011 Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 CD4 as a predictor of systemic inflammatory response and death at severe community-acquired pneumonia Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Non-infectious pulmonary complications in immunocompromised (IC) patients. Associated pulmonary and systemic inflammatory response Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2003; 22: Suppl. 45, 2s Year: 2003 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Local and systemic inflammation in acute viral exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 251s Year: 2005 Down-regulation of pro-inflammatory response genes of circulating leukocytes in ICU patients with severe pneumonia meeting criteria of systemic inflammatory response syndrome (SIRS) Source: Eur Respir J 2003; 22: Suppl. 45, 543s Year: 2003 Expression of stress genes in circulating leucocytes: response to the systemic inflammation in patients with severe pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 231s Year: 2004 Systemic inflammatory response in relation to disease severity and nutritional depletion in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 31s Year: 2004 Difference of immune response in patients with severe acute pneumonia and lung abscesses Source: Eur Respir J 2004; 24: Suppl. 48, 189s Year: 2004 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Cachexia in patients with acute COPD exacerbations: relationship to pulmonary function, systemic inflammation and oxidative stress Source: Annual Congress 2008 - Comorbidities in COPD Year: 2008 Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007 Inflammation in COPD: a link to systemic comorbidities Source: Eur Respir Rev 2007; 16: 91-97 Year: 2007 Dysregulation of systemic and local immune response in cystic fibrosis patients with chronic P. aeruginosa infection Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004